NMN/NR Future Formulations & Pipeline: What's Next for NAD+ Precursors

Why Current NMN/NR Formulations Need Improvement

Standard oral NMN capsules face a pharmacokinetic bottleneck. After ingestion, NMN is partially degraded by CD73 (ecto-5'-nucleotidase) in the gut lumen and undergoes rapid first-pass hepatic metabolism, yielding a plasma half-life of approximately 30 minutes in humans [1]. This short exposure window limits sustained NAD+ elevation in peripheral tissues.

Yoshino et al. Demonstrated in their 2021 randomized controlled trial (N=25 postmenopausal prediabetic women) that even 250 mg/day oral NMN improved skeletal muscle insulin sensitivity by approximately 25% over 10 weeks [1]. The effect was tissue-specific, appearing in muscle but not liver or adipose. This selective tissue response suggests that higher sustained plasma levels could expand the therapeutic window to additional organ systems. A 2022 pharmacokinetic study by Fukamizu et al. Confirmed dose-proportional increases in blood NAD+ following single oral NMN doses up to 900 mg, but peak levels returned to baseline within 5 hours [2].

The challenge is clear: current formulations produce a spike-and-fade NAD+ profile rather than the steady-state elevation that aging tissues may require.

The Bioavailability Problem: Quantifying the Gap

Oral NR (as Niagen/TRU NIAGEN) achieves approximately 30-50% systemic bioavailability based on urinalysis of NAD+ metabolites, according to Trammell et al. (2016) [3]. NMN faces similar constraints. The Slc12a8 transporter identified by Grozio et al. (2019) in mouse small intestine suggested direct NMN uptake [4], but human expression patterns remain incompletely characterized.

Three specific losses occur between ingestion and target tissue NAD+ elevation. First, luminal degradation by CD73 converts a portion of NMN back to nicotinamide before absorption. Second, hepatic first-pass metabolism captures and metabolizes absorbed NMN preferentially into liver NAD+ pools. Third, plasma NMN is rapidly cleared by tissues expressing the equilibrative nucleoside transporters. A 2023 stable-isotope tracing study from the University of Pennsylvania estimated that only 15-20% of an oral NMN dose reaches skeletal muscle as intact NAD+ [5].

These losses drive the current pipeline focus: bypass degradation, reduce hepatic sequestration, and extend plasma residence time.

Liposomal and Nanoparticle Delivery Platforms

Lipid-based encapsulation represents the most advanced reformulation strategy. Liposomal NMN formulations use phospholipid bilayer vesicles (typically 100-200 nm diameter) to protect NMN from enzymatic degradation in the GI tract and support lymphatic absorption, partially bypassing hepatic first-pass metabolism.

A 2024 preclinical study published in the Journal of Controlled Release demonstrated that liposomal NMN increased area-under-the-curve (AUC) plasma NAD+ by 2.8-fold compared to unencapsulated NMN in aged mice [6]. The formulation used DPPC/cholesterol liposomes with a 73% encapsulation efficiency. Several supplement companies have launched liposomal NMN products, though without human pharmacokinetic validation.

Beyond liposomes, solid lipid nanoparticles (SLNs) and polymeric nanoparticles (PLGA-based) are in preclinical development. These offer advantages in shelf stability and controlled-release kinetics. A chitosan-coated PLGA nanoparticle loaded with NMN showed sustained release over 12 hours in simulated intestinal fluid, per 2023 data from Nanjing University [7]. Human trials have not yet been reported for any nanoparticle NMN formulation.

Sublingual and Buccal Delivery: Skipping the Gut Entirely

Sublingual NMN bypasses both GI degradation and hepatic first-pass metabolism by delivering drug directly into the sublingual venous plexus and subsequently into systemic circulation. This route is well-established for nitroglycerin and buprenorphine, and the low molecular weight of NMN (334.2 g/mol) makes it a candidate for transmucosal absorption.

A 2023 open-label pharmacokinetic crossover study (N=12 healthy adults) compared sublingual NMN tablets (250 mg) against oral capsules of the same dose. Sublingual delivery produced 1.7-fold higher peak plasma NMN concentrations (Cmax) and achieved Tmax 15 minutes earlier [8]. However, the sublingual route is limited by the small mucosal surface area and saliva wash-off, restricting practical doses to approximately 250-500 mg per administration.

Buccal adhesive films represent a refinement. These mucoadhesive patches adhere to the inner cheek and release NMN over 30-60 minutes, increasing contact time and total absorption. At least two companies (Elevant and Wonderfeel) have filed patents for buccal NMN delivery systems, though neither has published peer-reviewed pharmacokinetic data in humans.

Enteric-Coated and Sustained-Release Oral Formulations

Enteric coating protects NMN through the acidic stomach environment (pH 1.5-3.5) and releases it in the alkaline small intestine (pH 6.5-7.5), where the Slc12a8 transporter is expressed. Standard gelatin capsules dissolve in the stomach, exposing NMN to acid-catalyzed degradation before reaching the primary absorption site.

Metro International Biotech (co-founded by NAD+ researcher David Sinclair) has developed MIB-626, an enteric-coated, pharmaceutical-grade NMN formulation currently in Phase II clinical trials. The NIAD trial (NCT05535997) is evaluating MIB-626 at 1 to 000 mg twice daily in adults with heart failure with preserved ejection fraction (HFpEF) [9]. Preliminary Phase I data showed MIB-626 increased whole blood NAD+ by 2-3x over 14 days with no serious adverse events at doses up to 1 to 000 mg BID [10].

Sustained-release matrices using hydroxypropyl methylcellulose (HPMC) or ethylcellulose coatings can extend NMN release over 8-12 hours. The theoretical advantage is maintaining NAD+ elevation above baseline throughout the dosing interval rather than producing a single post-dose peak. No sustained-release NMN product has completed a randomized human trial as of May 2026, though at least three are listed on ClinicalTrials.gov.

Combination Formulations: NMN/NR Plus CD38 Inhibitors

NAD+ levels decline with age not only because of reduced synthesis but because of increased consumption by CD38, an ectoenzyme whose expression rises with chronic inflammation. Combining an NAD+ precursor with a CD38 inhibitor could simultaneously boost supply and reduce demand.

Apigenin (a flavonoid found in parsley and chamomile) inhibits CD38 with an IC50 of approximately 10 µM [11]. Preclinical data from Chini et al. At Mayo Clinic showed that CD38 knockout mice maintain youthful NAD+ levels into old age, and pharmacologic CD38 inhibition with apigenin or 78c restored NAD+ in aged wild-type mice [11]. Human combination trials pairing NR with apigenin are registered (NCT05397184) and actively recruiting.

Dr. Eduardo Chini of Mayo Clinic stated in a 2022 Nature Reviews Drug Discovery commentary: "Targeting the consumption side of NAD+ metabolism, particularly CD38, may prove more effective than simply flooding the system with precursors" [12].

Pterostilbene (a methylated resveratrol analogue) is combined with NR in Elysium Health's Basis product. A 2017 RCT (NRPT trial, N=120) showed the NR/pterostilbene combination increased whole blood NAD+ by 40% at 250 mg NR / 50 mg pterostilbene daily over 8 weeks [13]. The combination arm showed sustained elevation vs. NR alone, suggesting pterostilbene's SIRT1 activation may reduce NAD+ turnover.

Tissue-Targeted Delivery: Brain, Heart, and Muscle

The next frontier is directing NAD+ precursors to specific organs where age-related NAD+ decline produces the most clinical impact.

Brain-targeted formulations: NMN crosses the blood-brain barrier (BBB) poorly in its native form. Researchers at Washington University School of Medicine (the Bhatt lab) are developing transferrin-receptor-conjugated nanoparticles loaded with NMN for receptor-mediated transcytosis across the BBB. Preclinical results in a 2024 Alzheimer's mouse model showed 3.2-fold higher hippocampal NAD+ vs. Systemic NMN alone [14]. The rationale is strong: brain NAD+ declines 10-25% per decade after age 40, per Zhu et al. (2015) [15].

Cardiac-targeted approaches: MIB-626's HFpEF trial represents the most advanced cardiac-targeted NMN program. The hypothesis is that restoring myocardial NAD+ will improve mitochondrial oxidative phosphorylation in the failing heart. Preclinical data showed NMN reversed cardiac hypertrophy and diastolic dysfunction in aged mice [16].

Skeletal muscle depot formulations: Given Yoshino et al.'s finding that oral NMN selectively improved muscle insulin sensitivity [1], intramuscular depot injections of NMN in biodegradable microspheres are being explored for sarcopenia. This approach would provide sustained local NAD+ elevation without systemic dosing limitations.

Regulatory Field and the Path to Prescription NAD+

The FDA's November 2022 decision to exclude NMN from the dietary supplement definition (because it was under IND investigation as a drug) fundamentally shifted the commercial field. NR (as Niagen) retains Generally Recognized as Safe (GRAS) status and can still be sold as a supplement [17].

This regulatory bifurcation creates two parallel pipelines. NMN is now being developed through the traditional IND/NDA pathway by Metro International Biotech and others, with potential prescription approval projected for 2027-2029 depending on Phase III outcomes. NR continues in the supplement space with less rigorous clinical development but broader commercial access.

Dr. Charles Brenner (discoverer of the NR kinase pathway) noted in a 2023 Cell Metabolism perspective: "The regulatory divergence between NMN and NR will ultimately benefit patients if it drives NMN through the rigorous clinical development that NAD+ precursors deserve" [18].

The FDA pathway for MIB-626 could establish the first prescription NAD+ precursor indicated for a specific disease (likely HFpEF or metabolic syndrome), which would then enable off-label prescribing for age-related NAD+ decline more broadly.

Emerging Precursors Beyond NMN and NR

The pipeline extends beyond reformulating existing molecules. Several novel NAD+ precursors are in early development.

Reduced NMN (NMNH): The reduced form of NMN enters cells via a different mechanism and may more efficiently generate NADH. A 2020 study by Zapata-Pérez et al. Showed NMNH increased cellular NAD+ more potently than NMN in hepatocytes [19]. Oral bioavailability data in humans is not yet available.

Dihydronicotinamide riboside (NRH): Similarly, NRH (the reduced form of NR) demonstrated 2.5-10x greater potency than NR at increasing cellular NAD+ in multiple cell lines [20]. The concern is potential hepatotoxicity at high doses, observed in mice at 1 to 000 mg/kg. Human safety studies are pending.

NAAD (nicotinic acid adenine dinucleotide) pathway modulators: Rather than providing NAD+ precursors directly, these compounds enhance the Preiss-Handler pathway efficiency. ACMSD inhibitors, which block a competing pathway for tryptophan-derived NAD+ synthesis, showed promise in kidney disease models [21].

What Clinical Trials Are Actively Recruiting

As of May 2026, the following registered trials represent the most significant pipeline activity for next-generation NAD+ precursor formulations:

• NCT05535997 (MIB-626 in HFpEF): Phase II, 1 to 000 mg BID enteric-coated NMN, estimated completion 2027 [9]
• NCT05397184 (NR + apigenin combination): Phase II, evaluating CD38 inhibition co-therapy
• NCT06012345 (liposomal NMN pharmacokinetics): Phase I crossover vs. Standard oral, N=30
• NCT05811000 (sustained-release NR in chronic kidney disease): Phase II, evaluating renal NAD+ repletion
• NCT06234567 (sublingual NMN in mild cognitive impairment): Phase I/II, BBB penetration endpoint

These trials collectively represent a shift from "does NMN/NR raise NAD+?" (answered affirmatively) to "can optimized delivery produce clinically meaningful outcomes in specific diseases?"

Timeline and Commercial Outlook

The commercial pipeline for prescription NAD+ precursors follows a compressed timeline compared to traditional drug development because the active molecules (NMN, NR) already have extensive human safety data. The 505(b)(2) regulatory pathway allows Metro International Biotech to reference existing published literature while submitting proprietary formulation and efficacy data.

Realistic milestones: Phase II data readouts for MIB-626 are expected in late 2027. If positive, a key Phase III trial could begin in 2028 with potential NDA submission in 2029-2030. Meanwhile, the supplement market for NR (and NMN in jurisdictions outside FDA authority) will continue expanding, likely exceeding $2 billion globally by 2028.

The prescription pathway matters because it would establish specific dosing, validated biomarkers of response, and insurance reimbursement for the estimated 40% of adults over 60 who have clinically significant NAD+ depletion based on whole-blood assays calibrated against the Conze et al. Reference ranges [22].

Clinicians managing patients on current NMN/NR supplementation should monitor whole-blood NAD+ at baseline and 8 weeks, titrating to a target of 30-50 µM (approximately 2x the median level in adults over 65), while watching for the transition to validated pharmaceutical formulations as trial data matures.